Aktienanalyse zu Aurora Cannabis Inc. (ACB)ACBAurora Cannabis Inc.

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Aurora Cannabis Inc is currently not a strong buy due to its low RSI of 29.306, indicating oversold conditions, and a significant forward P/E of 109.89, suggesting overvaluation relative to earnings. However, the recent acquisition interest from Curaleaf, which raised its bid to $5, shows potential upside. The main risk is the volatility in stock performance, as it has seen a 25.14% decline over the past year, and a 11.14% drop in the last five days.